$CYRX
Cryoport, Inc. Stock $cyrx

$cyrx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000141057823000188 Filed on February 28, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$62.82M	$60.36M	$237.3M
YoY Change	20.1%	6.94%	6.59%
Cost Of Revenue	$35.75M	$34.08M	$133.4M
YoY Change	19.31%	2.26%	5.85%
Gross Profit	$27.07M	$26.28M	$103.9M
YoY Change	21.18%	13.69%	7.55%
Gross Profit Margin	43.1%	43.54%	43.78%
Selling, General & Admin	$33.24M	$32.63M	$120.1M
YoY Change	24.86%	18.3%	23.05%
% of Gross Profit	122.79%	124.2%	115.58%
Research & Development	$3.876M	$4.677M	$15.72M
YoY Change	9.55%	20.23%	-6.66%
% of Gross Profit	14.32%	17.8%	15.14%
Depreciation & Amortization	$6.404M	$6.134M	$22.77M
YoY Change	19.37%	15.67%	12.44%
% of Gross Profit	23.66%	23.34%	21.92%
Operating Expenses	$37.12M	$37.31M	$135.8M
YoY Change	23.07%	18.54%	18.68%
Operating Profit	-$10.05M	-$11.04M	-$31.90M
YoY Change	28.47%	31.97%	78.94%
Interest Expense	$1.509M	$1.221M	$6.142M
YoY Change	1.21%	139.88%	30.99%
% of Operating Profit
Other Income/Expense, Net	$4.963M	$1.855M	-$3.190M
YoY Change	-194.64%	-237.0%	-98.75%
Pretax Income	-$5.082M	-$7.959M	-$35.09M
YoY Change	-61.1%	-96.95%	-87.18%
Income Tax	$492.0K	$1.477M	$2.239M
% Of Pretax Income
Net Earnings	-$5.574M	-$11.44M	-$37.33M
YoY Change	-58.42%	-95.6%	-86.45%
Net Earnings / Revenue	-8.87%	-18.95%	-15.73%
Basic Earnings Per Share	-$0.16	-$0.24	-$0.93
Diluted Earnings Per Share	-$0.16	-$0.24	-$0.93
COMMON SHARES
Basic Shares Outstanding	48.34M	49.00M	48.99M
Diluted Shares Outstanding	48.36M		48.99M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$522.6M	$523.3M	$523.3M
YoY Change	-12.83%	-16.77%	-16.77%
Cash & Equivalents	$38.54M	$36.60M	$1.843M
Short-Term Investments	$484.1M	$488.6M	$488.6M
Other Short-Term Assets	$9.959M	$9.317M	$9.317M
YoY Change	19.08%	5.83%	5.83%
Inventory	$26.49M	$27.68M	$27.68M
Prepaid Expenses
Receivables	$45.57M	$43.86M	$43.86M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$604.6M	$604.2M	$604.2M
YoY Change	-9.18%	-12.88%	-12.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$71.26M	$63.60M	$90.48M
YoY Change	40.46%	29.73%	29.81%
Goodwill	$151.6M	$151.1M
YoY Change	3.43%	2.83%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.155M	$947.0K	$1.964M
YoY Change	-19.53%	126.01%	43.46%
Total Long-Term Assets	$443.5M	$434.6M	$434.6M
YoY Change	6.72%	3.6%	3.6%
TOTAL ASSETS
Total Short-Term Assets	$604.6M	$604.2M	$604.2M
Total Long-Term Assets	$443.5M	$434.6M	$434.6M
Total Assets	$1.048B	$1.039B	$1.039B
YoY Change	-3.07%	-6.67%	-6.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$25.86M	$28.05M	$28.05M
YoY Change	-8.65%	-1.88%	-1.88%
Accrued Expenses	$14.54M	$12.18M	$12.18M
YoY Change	-6.57%	-9.48%	-9.48%
Deferred Revenue	$1.009M	$439.0K
YoY Change	95.16%	-19.74%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$61.00K	$60.00K	$60.00K
YoY Change	15.09%	-1.64%	-1.64%
Total Short-Term Liabilities	$41.58M	$40.85M	$40.85M
YoY Change	-6.43%	-4.21%	-4.21%
LONG-TERM LIABILITIES
Long-Term Debt	$407.9M	$407.3M	$407.3M
YoY Change	0.51%	0.49%	0.49%
Other Long-Term Liabilities	$368.0K	$451.0K	$29.85M
YoY Change	-1.08%	29.23%	55.7%
Total Long-Term Liabilities	$368.0K	$451.0K	$437.1M
YoY Change	-1.08%	29.23%	2.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.58M	$40.85M	$40.85M
Total Long-Term Liabilities	$368.0K	$451.0K	$437.1M
Total Liabilities	$487.6M	$482.9M	$482.9M
YoY Change	3.33%	2.5%	2.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$548.4M	-$542.8M
YoY Change	12.08%	16.1%
Common Stock	$1.118B	$1.115B
YoY Change	1.4%	1.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$37.90M
YoY Change
Treasury Stock Shares
Shareholders Equity	$560.5M	$555.8M	$555.8M
YoY Change
Total Liabilities & Shareholders Equity	$1.048B	$1.039B	$1.039B
YoY Change	-3.07%	-6.67%	-6.67%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$5.574M	-$11.44M	-$37.33M
YoY Change	-58.42%	-95.6%	-86.45%
Depreciation, Depletion And Amortization	$6.404M	$6.134M	$22.77M
YoY Change	19.37%	15.67%	12.44%
Cash From Operating Activities	$2.774M	$3.654M	-$1.851M
YoY Change	429.39%	39.79%	-122.78%
INVESTING ACTIVITIES
Capital Expenditures	$9.569M	$8.464M	$22.11M
YoY Change	125.42%	-199.06%	-7.43%
Acquisitions			$6.554M
YoY Change			18.3%
Other Investing Activities	$8.826M	$15.59M	-$35.48M
YoY Change	15.43%	-108.32%	-92.01%
Cash From Investing Activities	-$1.383M	$7.124M	-$59.68M
YoY Change	-145.34%	-103.64%	-87.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$37.96M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	71.00K	-5.306M	-39.17M
YoY Change	-100.88%	-101.84%	-106.94%
NET CHANGE
Cash From Operating Activities	2.774M	3.654M	-1.851M
Cash From Investing Activities	-1.383M	7.124M	-59.68M
Cash From Financing Activities	71.00K	-5.306M	-39.17M
Net Change In Cash	1.943M	5.472M	-102.5M
YoY Change	-141.76%	-94.25%	-200.27%
FREE CASH FLOW
Cash From Operating Activities	$2.774M	$3.654M	-$1.851M
Capital Expenditures	$9.569M	$8.464M	$22.11M
Free Cash Flow	-$6.795M	-$4.810M	-$23.96M
YoY Change	82.61%	-143.11%	52.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48987295
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45927591
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38582432
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001124524
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49616154
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48334280
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.94
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.18
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-34632
CY2022	dei	Entity Registrant Name EntityRegistrantName	CRYOPORT, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-0313393
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	112 Westwood Place
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 350
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Brentwood
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37027
CY2022	dei	City Area Code CityAreaCode	949
CY2022	dei	Local Phone Number LocalPhoneNumber	470-2300
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2022	dei	Trading Symbol TradingSymbol	CYRX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1100000000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48335779
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Irvine
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36595000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	139101000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	486728000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	489698000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1300000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1200000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	43858000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39412000
CY2022Q4	us-gaap	Inventory Net InventoryNet	27678000
CY2021Q4	us-gaap	Inventory Net InventoryNet	16501000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9317000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8804000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	604176000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	693516000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	63603000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	191009000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49029000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26877000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20675000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48334280
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	201427000
CY2022Q4	us-gaap	Goodwill Goodwill	151117000
CY2021Q4	us-gaap	Goodwill Goodwill	146954000
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	1017000
CY2021Q4	us-gaap	Deposits Assets DepositsAssets	950000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	947000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	419000
CY2022Q4	us-gaap	Assets Assets	1038746000
CY2021Q4	us-gaap	Assets Assets	1112970000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	28046000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	28583000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8458000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9912000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	439000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	547000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3720000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3542000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	128000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	61000
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	60000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40851000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	42645000
CY2022	cyrx	Convertible Subordinated Debt Discount ConvertibleSubordinatedDebtDiscount	10100000
CY2021	cyrx	Convertible Subordinated Debt Discount ConvertibleSubordinatedDebtDiscount	12700000
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	406708000
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	404171000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	0
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	50000.00
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	355000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1086000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24721000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18144000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	216000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	51000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4929000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4018000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	451000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	298000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	4677000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	729000
CY2022Q4	us-gaap	Liabilities Liabilities	482908000
CY2021Q4	us-gaap	Liabilities Liabilities	471142000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49616154
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	48000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	50000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1114896000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1100287000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-542832000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-467541000
CY2022Q4	cyrx	Accumulated Other Comprehensive Income Loss AccumulatedOtherComprehensiveIncomeLoss	-34549000
CY2021Q4	cyrx	Accumulated Other Comprehensive Income Loss AccumulatedOtherComprehensiveIncomeLoss	-1243000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	555838000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	641828000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1038746000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1112970000
CY2022	us-gaap	Revenues Revenues	237277000
CY2021	us-gaap	Revenues Revenues	222608000
CY2020	us-gaap	Revenues Revenues	78696000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	133404000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	126031000
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	42362000
CY2022	us-gaap	Gross Profit GrossProfit	103873000
CY2021	us-gaap	Gross Profit GrossProfit	96577000
CY2020	us-gaap	Gross Profit GrossProfit	36334000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	120055000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	97563000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	56860000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15722000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16843000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9484000
CY2022	us-gaap	Operating Expenses OperatingExpenses	135777000
CY2021	us-gaap	Operating Expenses OperatingExpenses	114406000
CY2020	us-gaap	Operating Expenses OperatingExpenses	66344000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-31904000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-17829000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-30010000
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	8474000
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	3253000
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	761000
CY2022	us-gaap	Interest Expense InterestExpense	6142000
CY2021	us-gaap	Interest Expense InterestExpense	4689000
CY2020	us-gaap	Interest Expense InterestExpense	2560000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-251754000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5522000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2823000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-929000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3190000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-256013000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2728000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35094000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-273842000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32738000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2239000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1686000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-45000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37333000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-275528000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32693000
CY2020	cyrx	Deemed Dividend On Series C Convertible Preferred Stock Value DeemedDividendOnSeriesCConvertiblePreferredStockValue	39492000
CY2022	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	8000000
CY2021	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	8196000
CY2020	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	2844000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45333000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-283724000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75029000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.18
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.94
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48987295
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45927591
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38582432
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37333000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-275528000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32693000
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	23439000
CY2021	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	3958000
CY2020	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-161000
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	46000
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	27000
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	3000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9821000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2634000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5263000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-33306000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6619000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5421000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-70639000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-282147000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27272000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	126281000
CY2020	us-gaap	Profit Loss ProfitLoss	-32693000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5421000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8833000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	83000
CY2020	cyrx	Adjustments To Additional Paid In Convertible Preferred Stock AdjustmentsToAdditionalPaidInConvertiblePreferredStock	237225000
CY2020	cyrx	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	9388000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	382698000
CY2021	us-gaap	Profit Loss ProfitLoss	-275528000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6619000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15334000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11000
CY2021	cyrx	Adjustments To Additional Paid In Capital Conversion Costs AdjustmentsToAdditionalPaidInCapitalConversionCosts	-1800000
CY2021	cyrx	Issuance Of Common Stock In Direct Placement Net IssuanceOfCommonStockInDirectPlacementNet	248911000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	269825000
CY2022	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	4137000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-469254000
CY2021	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	7270000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8996000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	641828000
CY2022	us-gaap	Profit Loss ProfitLoss	-37333000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-33306000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20082000
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	479000
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	37960000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2048000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	555838000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37333000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-275528000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32693000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-251754000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22765000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20247000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9869000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2581000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1236000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	437000
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-11406000
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1386000
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	845000
CY2021	cyrx	Realized Loss On Investments In Equity Securities RealizedLossOnInvestmentsInEquitySecurities	0
CY2020	cyrx	Realized Loss On Investments In Equity Securities RealizedLossOnInvestmentsInEquitySecurities	1090000
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment	-102000
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment	-81000
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment	-32000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20082000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15345000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8916000
CY2022	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-800000
CY2021	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-542000
CY2020	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-384000
CY2022	cyrx	Excess And Obsolete Inventory ExcessAndObsoleteInventory	651000
CY2021	cyrx	Excess And Obsolete Inventory ExcessAndObsoleteInventory	0
CY2020	cyrx	Excess And Obsolete Inventory ExcessAndObsoleteInventory	0
CY2022	cyrx	Gain Loss On Insurance Settlement GainLossOnInsuranceSettlement	4815000
CY2021	cyrx	Gain Loss On Insurance Settlement GainLossOnInsuranceSettlement	0
CY2020	cyrx	Gain Loss On Insurance Settlement GainLossOnInsuranceSettlement	0
CY2022	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	9883000
CY2021	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	0
CY2020	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	0
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	234000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	26000
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	197000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	216000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0
CY2020	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	2617000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14204000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5979000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1322000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1598000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3056000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7520000
CY2022	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	60000
CY2021	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-211000
CY2020	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	152000
CY2022	cyrx	Right Of Use Asset Obtained In Exchange For Operating Leases Liability RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability	-569000
CY2021	cyrx	Right Of Use Asset Obtained In Exchange For Operating Leases Liability RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability	-562000
CY2020	cyrx	Right Of Use Asset Obtained In Exchange For Operating Leases Liability RightOfUseAssetObtainedInExchangeForOperatingLeasesLiability	-134000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6483000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-398000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4245000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1569000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2522000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3143000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-530000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	102000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-309000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-411000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	231000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-499000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1851000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8126000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14866000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22107000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23882000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8918000
CY2022	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	3000000
CY2021	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	0
CY2020	us-gaap	Proceeds From Insurance Settlement Investing Activities ProceedsFromInsuranceSettlementInvestingActivities	0
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	163788000
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	482707000
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	158736000
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	131858000
CY2021	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	44000000
CY2020	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	149233000
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	614000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	255000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	200000
CY2022	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	1476000
CY2021	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	870000
CY2020	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	551000
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	6554000
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	5540000
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	363140000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-59681000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-382312000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2048000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	8995000
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	9388000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	37960000
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	248911000
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	237225000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28160000
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	269825000
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2022	cyrx	Repayment Of Finance Lease Liabilities RepaymentOfFinanceLeaseLiabilities	82000
CY2021	cyrx	Repayment Of Finance Lease Liabilities RepaymentOfFinanceLeaseLiabilities	60000
CY2020	cyrx	Repayment Of Finance Lease Liabilities RepaymentOfFinanceLeaseLiabilities	70000
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3180000
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3397000
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	40068000
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	115000000
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	4118000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-39174000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	564342000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	385585000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1800000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-986000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1231000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-102506000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	102228000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10362000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139101000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36873000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47235000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36595000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139101000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36873000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	3628000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	3297000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1823000
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	1979000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	1315000
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	60000
CY2022	cyrx	Non Cash Net Unrealized Gain Loss On Available For Sale Securities NonCashNetUnrealizedGainLossOnAvailableForSaleSecurities	23439000
CY2021	cyrx	Non Cash Net Unrealized Gain Loss On Available For Sale Securities NonCashNetUnrealizedGainLossOnAvailableForSaleSecurities	3958000
CY2020	cyrx	Non Cash Net Unrealized Gain Loss On Available For Sale Securities NonCashNetUnrealizedGainLossOnAvailableForSaleSecurities	161000
CY2022	cyrx	Reclassification Of Realized Gain On Available For Sale Debt Securities To Earnings ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings	46000
CY2021	cyrx	Reclassification Of Realized Gain On Available For Sale Debt Securities To Earnings ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings	27000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1412000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	499000
CY2020	cyrx	Reclassification Of Realized Gain On Available For Sale Debt Securities To Earnings ReclassificationOfRealizedGainOnAvailableForSaleDebtSecuritiesToEarnings	3000
CY2021	cyrx	Purchase Of Equipment Through Capital Lease Obligation PurchaseOfEquipmentThroughCapitalLeaseObligation	0
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1003000
CY2020	cyrx	Purchase Of Equipment Through Capital Lease Obligation PurchaseOfEquipmentThroughCapitalLeaseObligation	205000
CY2022	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stocks Value PaidInKindDividendOnSeriesCConvertiblePreferredStocksValue	8000000
CY2021	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stocks Value PaidInKindDividendOnSeriesCConvertiblePreferredStocksValue	8196000
CY2020	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stocks Value PaidInKindDividendOnSeriesCConvertiblePreferredStocksValue	2844000
CY2021	cyrx	Common Stock Issued For Conversion Of Debt And Accrued Interest CommonStockIssuedForConversionOfDebtAndAccruedInterest	765000
CY2020	cyrx	Common Stock Issued For Conversion Of Debt And Accrued Interest CommonStockIssuedForConversionOfDebtAndAccruedInterest	0
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1. Nature of the Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cryoport serves the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the biopharma/pharma, animal health, and reproductive medicine markets. Our mission is to support life and health worldwide and we are continuously developing, implementing, and leveraging our supply chain platform, which is designed to deliver comprehensive, unparalleled, highly differentiated temperature-controlled logistics, packaging, storage, cryogenic systems, informatics, and related services for life science products, regenerative medicine, cellular therapies, and treatments that require unique, specialized cold chain management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company completed both the acquisition of MVE Biological Solutions (the “MVE Acquisition”) and the acquisition of CRYOPDP (the “CRYOPDP Acquisition”). In the second quarter of 2021, the Company completed the acquisitions of Critical Transport Solutions Australia (CTSA) in Australia and F-airGate in Belgium to further enhance CRYOPDP’s existing global temperature-controlled supply chain capabilities in the APAC (Asia-Pacific) and EMEA (Europe, the Middle East, and Africa) regions. In April 2022, the Company completed the acquisition of Cell&Co BioServices (Cell&Co) in Clermont-Ferrand, France. In July 2022, the Company completed the acquisition of Polar Expres in Madrid, Spain, which provides temperature-controlled logistics solutions dedicated to the life sciences industry, and the acquisition of Cell Matters in Liège, Belgium, which provides cryo-process optimization, cryoprocessing, and cryopreservation solutions to the life sciences industry (See Note 3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”</p>
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2022	cyrx	Maturity Period Of Highly Liquid Investments MaturityPeriodOfHighlyLiquidInvestments	P90D
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, fair value of short-term investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates, including valuation multiples utilized in the market approach used in impairment assessments, estimated fair values of intangible assets and goodwill, intangible asset useful lives and amortization methods, inventory excess and obsolescence reserve, contingent consideration liability, equity-based instruments, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future events, including the extent and the duration of the COVID-19 related economic impacts, and their effects cannot be predicted with certainty, and, accordingly the Company’s accounting estimates require the exercise of judgment.</p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. From time to time, we maintain cash, cash equivalent and short-term investment balances in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”). Primarily all of our cash, cash equivalents and short-term investments at December 31, 2022 were in excess of amounts insured by the FDIC and SIPC. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure. We manage such risks in our portfolio by investing in highly liquid, highly rated instruments, and limit investing in long-term maturity instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investment policy requires that purchased instruments in marketable securities may only be in highly rated instruments, which are primarily U.S. Treasury bills or treasury-backed securities, and also limits our investment in securities of any single issuer.</p>
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1300000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1200000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37333000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-275528000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32693000
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q2	cyrx	Statutory Credit Usage Limit For Research And Development For Tax Relief StatutoryCreditUsageLimitForResearchAndDevelopmentForTaxRelief	5000000
CY2021Q1	cyrx	Executive Compensation Limit ExecutiveCompensationLimit	1000000
CY2022	us-gaap	Revenue Practical Expedient Remaining Performance Obligation RevenuePracticalExpedientRemainingPerformanceObligation	true
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	700000
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	500000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	400000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	500000
CY2022	cyrx	Contract With Customer Liability Revenue Recognized Excluding Opening Balance ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance	1400000
CY2021	cyrx	Contract With Customer Liability Revenue Recognized Excluding Opening Balance ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance	300000
CY2020	cyrx	Contract With Customer Liability Revenue Recognized Excluding Opening Balance ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance	400000
CY2020	cyrx	Deemed Dividend On Series C Convertible Preferred Stock Value DeemedDividendOnSeriesCConvertiblePreferredStockValue	39492000
CY2022	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	8000000
CY2021	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	8196000
CY2020	cyrx	Paid In Kind Dividend On Series C Convertible Preferred Stock Value PaidInKindDividendOnSeriesCConvertiblePreferredStockValue	2844000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45333000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-283724000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75029000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48987295
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48987295
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45927591
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45927591
CY2022	us-gaap	Revenues Revenues	237277000
CY2021	us-gaap	Revenues Revenues	222608000
CY2020	us-gaap	Revenues Revenues	78696000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38582432
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38582432
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.18
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.18
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.94
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.94
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14609804
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15290040
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17205023
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-9800000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2600000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	5200000
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior year amounts in sales and marketing expense have been reclassified to selling, general and administrative expense to conform to the current period presentation, which reflects how the Company tracks operating costs. These reclassifications had no effect on the previously reported net loss.</p>
CY2022Q2	cyrx	Business Combination Acquisition Equity Interest Shares Issuable BusinessCombinationAcquisitionEquityInterestSharesIssuable	400000
CY2022Q2	us-gaap	Business Combination Acquired Receivables Fair Value BusinessCombinationAcquiredReceivablesFairValue	2000000.0
CY2022Q2	us-gaap	Business Combination Acquired Receivables Fair Value BusinessCombinationAcquiredReceivablesFairValue	2200000
CY2022Q2	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	3400000
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	2800000
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	2800000
CY2022Q3	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	1400000
CY2022Q3	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	1400000
CY2022Q3	us-gaap	Business Combination Acquired Receivables Fair Value BusinessCombinationAcquiredReceivablesFairValue	1400000
CY2022Q3	us-gaap	Business Combination Acquired Receivables Fair Value BusinessCombinationAcquiredReceivablesFairValue	1400000
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	1700000
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	1000000.0
CY2022	cyrx	Business Combination Prior Period Adjustment Deferred Tax BusinessCombinationPriorPeriodAdjustmentDeferredTax	800000
CY2022Q4	us-gaap	Cash Cash	34752000
CY2021Q4	us-gaap	Cash Cash	27788000
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1843000
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	111313000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36595000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	139101000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	486728000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	489698000
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	523323000
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	628799000
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	410390000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1248000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	24687000
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	386951000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	129568000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	126776000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	280822000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	260175000
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	410390000
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	386951000
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	383547000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3867000
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	379692000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	39081000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	39035000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	328776000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	325047000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	15690000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	15610000
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	383547000
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	379692000
CY2022Q4	cyrx	Available For Sale Securities Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesUnrealizedLossPositionLessThanTwelveMonthsFairValue	80958000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	2515000
CY2022Q4	cyrx	Available For Sale Securities Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesUnrealizedLossPositionTwelveMonthsOrLongerFairValue	305992000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	22172000
CY2022Q4	cyrx	Available For Sale Securities Unrealized Loss Position Fair Value AvailableForSaleSecuritiesUnrealizedLossPositionFairValue	386951000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	24687000
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-100000
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-80000.00
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	30000.00
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	99800000
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	110000000.0
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-11406000
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-1386000
CY2020	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-245000
CY2020	cyrx	Equity Securities Realized Gain Loss Sold EquitySecuritiesRealizedGainLossSold	1090000
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-11406000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-1386000
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	845000
CY2021Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	5808000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	18287000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	11846000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	895000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	670000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8496000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3985000
CY2022Q4	us-gaap	Inventory Net InventoryNet	27678000
CY2021Q4	us-gaap	Inventory Net InventoryNet	16501000
CY2022Q4	cyrx	Cryogenic Shippers And Data Loggers CryogenicShippersAndDataLoggers	11373000
CY2021Q4	cyrx	Cryogenic Shippers And Data Loggers CryogenicShippersAndDataLoggers	9343000
CY2022Q4	cyrx	Freezers Gross FreezersGross	7320000
CY2021Q4	cyrx	Freezers Gross FreezersGross	5341000
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	3760000
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2204000
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	2824000
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	2384000
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	16492000
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	12405000
CY2022Q4	cyrx	Trucks And Autos Gross TrucksAndAutosGross	853000
CY2021Q4	cyrx	Trucks And Autos Gross TrucksAndAutosGross	497000
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	27083000
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	21657000
CY2022Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	4473000
CY2022Q4	us-gaap	Land Land	813000
CY2021Q4	us-gaap	Land Land	806000
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	15947000
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	8583000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	90938000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	69028000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27335000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19999000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	63603000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49029000
CY2022	us-gaap	Depreciation Depreciation	7700000
CY2021	us-gaap	Depreciation Depreciation	5800000
CY2020	us-gaap	Depreciation Depreciation	3200000
CY2022Q4	cyrx	Leases Equipment Under Finance Leases Amount LeasesEquipmentUnderFinanceLeasesAmount	500000
CY2021Q4	cyrx	Leases Equipment Under Finance Leases Amount LeasesEquipmentUnderFinanceLeasesAmount	300000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	200000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	100000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	63603000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49029000
CY2021Q4	us-gaap	Goodwill Goodwill	146954000
CY2020Q4	us-gaap	Goodwill Goodwill	145282000
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-5391000
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-419000
CY2022Q4	us-gaap	Goodwill Goodwill	151117000
CY2021Q4	us-gaap	Goodwill Goodwill	146954000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	231344000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	40335000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	191009000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	224839000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23412000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	201427000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15100000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14400000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6600000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	15269000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	14663000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	12739000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	12486000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	12261000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	78027000
CY2022Q4	cyrx	Future Amortization Of Finite Lived Intangible Assets FutureAmortizationOfFiniteLivedIntangibleAssets	145445000
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6007000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8003000
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2451000
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1909000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8458000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9912000
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	10136000
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	12673000
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	406708000
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	404171000
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3496000
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1005000
CY2020	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	2108000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2537000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3419000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	437000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	6033000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	4424000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	2545000
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	117.59
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	100000000.0
CY2022Q4	us-gaap	Long Term Debt Term LongTermDebtTerm	P5Y
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	5505000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	4556000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1835000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	79000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	61000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	56000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	12000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	8000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	10000
CY2022	cyrx	Finance Lease Cost FinanceLeaseCost	91000
CY2021	cyrx	Finance Lease Cost FinanceLeaseCost	69000
CY2020	cyrx	Finance Lease Cost FinanceLeaseCost	66000
CY2022	us-gaap	Lease Cost LeaseCost	5596000
CY2021	us-gaap	Lease Cost LeaseCost	4625000
CY2020	us-gaap	Lease Cost LeaseCost	1901000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	4733000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3993000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1680000
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	82000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	65000
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	77000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	70000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	67000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	58000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	12384000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10175000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10708000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	259000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	230000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y4M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M24D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.095
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.051
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.078
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.053
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5762000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	152000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5493000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	91000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4352000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	85000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3918000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	56000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3345000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	8000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	26813000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	49683000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	392000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	21242000
CY2022Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	48000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	28441000
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	344000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3720000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	128000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24721000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	216000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	28441000
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	344000
CY2022Q1	cyrx	Estimated Revenue Impact Due To Catastrophes EstimatedRevenueImpactDueToCatastrophes	9400000
CY2020	cyrx	Deferred Income Tax Expense Benefit Total DeferredIncomeTaxExpenseBenefitTotal	-527000
CY2022	cyrx	Proceeds From Insurance Settlement ProceedsFromInsuranceSettlement	12900000
CY2022Q4	cyrx	Gain Loss On Insurance Settlement For Reimbursement Of Property And Equipment GainLossOnInsuranceSettlementForReimbursementOfPropertyAndEquipment	600000
CY2022Q4	cyrx	Gain Loss On Insurance Settlement Related To Business Interruption GainLossOnInsuranceSettlementRelatedToBusinessInterruption	4200000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	11500
CY2022Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	100000000.0
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1604994
CY2022	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	23.63
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	37900000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022	us-gaap	Dividends Paidinkind DividendsPaidinkind	8000000.0
CY2021	us-gaap	Dividends Paidinkind DividendsPaidinkind	8200000
CY2020Q4	cyrx	Deemed Dividend DeemedDividend	39500000
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17755771
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2020	cyrx	Warrants Exercised Intrinsic Value WarrantsExercisedIntrinsicValue	17600000
CY2022	cyrx	Number Of Stock Incentive Plans NumberOfStockIncentivePlans	5
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.021
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.037
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0047
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0118
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0031
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0170
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.675
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.786
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.644
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.808
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.698
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.827
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	20082000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	15345000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	8916000
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5200000
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	57500000
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	24100000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2239000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1686000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-45000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40927000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	4081000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37022000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35094000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-273842000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32738000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	11000
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	70000
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	112000
CY2020	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	110000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2634000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1783000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	361000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2704000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1895000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	482000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7712000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-11646000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-8245000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-191000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1564000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-832000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1545000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1126000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-738000
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	8983000
CY2021	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	14127000
CY2020	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	9288000
CY2022	cyrx	Deferred Income Tax Expense Benefit Total DeferredIncomeTaxExpenseBenefitTotal	-465000
CY2021	cyrx	Deferred Income Tax Expense Benefit Total DeferredIncomeTaxExpenseBenefitTotal	-209000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4847000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4152000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	3208000
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	9365000
CY2021Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	1011000
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	2724000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2046000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	860000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1929000
CY2022Q4	cyrx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	4712000
CY2021Q4	cyrx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	3471000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	69562000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	50793000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61700000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45885000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7862000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4908000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	2779000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	1650000
CY2022Q4	cyrx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	4382000
CY2021Q4	cyrx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	3268000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	3906000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2938000
CY2022Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	777000
CY2021Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	651000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11844000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8507000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3982000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3599000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3982000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3599000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7370000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-57507000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6875000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	296000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1222000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1077000
CY2021	cyrx	Income Tax Reconciliation Non Deductible Expense Loss On Debt Extinguishment IncomeTaxReconciliationNonDeductibleExpenseLossOnDebtExtinguishment	50817000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1881000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-7543000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2683000
CY2021	cyrx	Effective Income Tax Rate Reconciliation Deemed Foreign Dividend Income EffectiveIncomeTaxRateReconciliationDeemedForeignDividendIncome	198000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-590000
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	352000
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	813000
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-375000
CY2022	cyrx	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	160000
CY2020	cyrx	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	528000
CY2022	cyrx	Effective Income Tax Rate Reconciliation Executive Compensation Amount EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount	83000
CY2021	cyrx	Effective Income Tax Rate Reconciliation Executive Compensation Amount EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount	1894000
CY2020	cyrx	Effective Income Tax Rate Reconciliation Executive Compensation Amount EffectiveIncomeTaxRateReconciliationExecutiveCompensationAmount	609000
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-113000
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2021Q1	us-gaap	Revenues Revenues	53284000
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	105000
CY2021Q2	us-gaap	Revenues Revenues	56191000
CY2021Q3	us-gaap	Revenues Revenues	56693000
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	408000
CY2022	cyrx	Effective Income Tax Rate Reconciliation Contingencies EffectiveIncomeTaxRateReconciliationContingencies	-1443000
CY2021	cyrx	Effective Income Tax Rate Reconciliation Contingencies EffectiveIncomeTaxRateReconciliationContingencies	8000
CY2020	cyrx	Effective Income Tax Rate Reconciliation Contingencies EffectiveIncomeTaxRateReconciliationContingencies	112000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8983000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14123000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9308000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2239000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1686000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-45000
CY2022	cyrx	Operating Loss Carryforwards Percent OperatingLossCarryforwardsPercent	0.80
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	20200000
CY2022Q4	cyrx	Research And Experimental Expenditures And Software Development Costs To Capital Account ResearchAndExperimentalExpendituresAndSoftwareDevelopmentCostsToCapitalAccount	13100000
CY2022	cyrx	Amortization For Research And Experimental Expenditures And Software Development Costs AmortizationForResearchAndExperimentalExpendituresAndSoftwareDevelopmentCosts	1300000
CY2022Q1	us-gaap	Revenues Revenues	52302000
CY2022Q2	us-gaap	Revenues Revenues	64153000
CY2022Q3	us-gaap	Revenues Revenues	60464000
CY2022Q4	us-gaap	Revenues Revenues	60358000
CY2022Q1	us-gaap	Gross Profit GrossProfit	22341000
CY2022Q2	us-gaap	Gross Profit GrossProfit	28838000
CY2022Q3	us-gaap	Gross Profit GrossProfit	26417000
CY2022Q4	us-gaap	Gross Profit GrossProfit	26277000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7819000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5247000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7803000
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-11035000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15404000
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11177000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7316000
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11436000
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2021Q4	us-gaap	Revenues Revenues	56440000
CY2021Q1	us-gaap	Gross Profit GrossProfit	24550000
CY2021Q2	us-gaap	Gross Profit GrossProfit	25402000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1142000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3748000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4576000
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-8362000
CY2021Q3	us-gaap	Gross Profit GrossProfit	23513000
CY2021Q4	us-gaap	Gross Profit GrossProfit	23113000
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5723000
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7389000
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8526000
CY2021Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-262086000
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.46
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.46
CY2020Q1	us-gaap	Revenues Revenues	9774000
CY2020Q2	us-gaap	Revenues Revenues	9389000
CY2020Q3	us-gaap	Revenues Revenues	11172000
CY2020Q4	us-gaap	Revenues Revenues	48361000
CY2020Q1	us-gaap	Gross Profit GrossProfit	5258000
CY2020Q2	us-gaap	Gross Profit GrossProfit	5127000
CY2020Q3	us-gaap	Gross Profit GrossProfit	6055000
CY2020Q4	us-gaap	Gross Profit GrossProfit	19894000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3586000
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5845000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10732000
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-9847000
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3943000
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5803000
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11418000
CY2020Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-53866000
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32

Files In Submission

Name	View Source	Status
0001410578-23-000188-index-headers.html	Edgar Link	pending
0001410578-23-000188-index.html	Edgar Link	pending
0001410578-23-000188.txt	Edgar Link	pending
0001410578-23-000188-xbrl.zip	Edgar Link	pending
cyrx-20221231.xsd	Edgar Link	pending
cyrx-20221231x10k.htm	Edgar Link	pending
cyrx-20221231x10k004.jpg	Edgar Link	pending
cyrx-20221231x10k008.jpg	Edgar Link	pending
cyrx-20221231x10k009.jpg	Edgar Link	pending
cyrx-20221231x10k010.jpg	Edgar Link	pending
cyrx-20221231x10k011.jpg	Edgar Link	pending
cyrx-20221231x10k012.jpg	Edgar Link	pending
cyrx-20221231xex21.htm	Edgar Link	pending
cyrx-20221231xex23d1.htm	Edgar Link	pending
cyrx-20221231xex31d1.htm	Edgar Link	pending
cyrx-20221231xex31d2.htm	Edgar Link	pending
cyrx-20221231xex32d1.htm	Edgar Link	pending
cyrx-20221231xex32d2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
cyrx-20221231_def.xml	Edgar Link	unprocessable
cyrx-20221231_lab.xml	Edgar Link	unprocessable
cyrx-20221231_pre.xml	Edgar Link	unprocessable
cyrx-20221231x10k_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cyrx-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYRX
Cryoport, Inc. Stock $cyrx

2023 Q1 Form 10-K Financial Statement

#000141057823000188 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX Cryoport, Inc. Stock $cyrx

2023 Q1 Form 10-K Financial Statement

#000141057823000188 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX
Cryoport, Inc. Stock $cyrx